Independent analysis of commercial transformation across life sciences in Europe

Life Sciences Commercial Transformation in Europe — Strategy, Market Signals, and What Comes Next

Commercialization, regulation, AI, and operating-model shifts shaping pharma, MedTech, and digital health in Europe – from an operator’s perspective.

Read the Weekly Signal About Piotr Wrzosinski

Weekly Life Sciences Signal

Weekly analysis of funding, regulation, AI, commercial moves, and execution signals shaping life sciences in Europe.

• Weekly Signal

  Europe Life Sciences Weekly Signal #34

  ByPiotr Wrzosinski 26/04/202626/04/2026

  Week of 20–26 April 2026 This was a week of arrivals. Lilly moved to acquire an in vivo CAR-T platform for up to $7 billion. Sanofi posted strong Q1 numbers just before Belén Garijo formally takes over as CEO. Roche grew globally, but Europe remained the softer regional signal. Novartis withdrew a Pluvicto EU expansion…

• Weekly Signal

  Europe Life Sciences Weekly Signal #33

  ByPiotr Wrzosinski 19/04/202619/04/2026

  Week of 13–19 April 2026 The lazy read of this week is that healthcare is still “investing in innovation”. The more useful read is harsher: the market is rewarding operating discipline, evidence quality and control of infrastructure. AI is moving out of demo mode, regulators are still demanding harder proof, and the dull parts of…

• Weekly Signal

  Europe Life Sciences Weekly Brief

  ByPiotr Wrzosinski 12/04/202612/04/2026

  Week of 6–12 April 2026 (#32) The pattern this week is not that innovation has slowed. It is that the market is becoming less tolerant of loose sequencing. Capital is still moving, but more selectively and more obviously towards platform capability rather than isolated stories. Regulators are still opening doors, but increasingly only for companies…